Eterna Therapeutics Inc (ERNA) - Total Assets
Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) holds total assets worth $6.17 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Eterna Therapeutics Inc (ERNA) net assets for net asset value and shareholders' equity analysis.
Eterna Therapeutics Inc - Total Assets Trend (2006–2024)
This chart illustrates how Eterna Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Eterna Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Eterna Therapeutics Inc's total assets of $6.17 Million consist of 44.6% current assets and 55.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.8% |
| Accounts Receivable | $437.00K | 8.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $2.04 Million | 38.8% |
Asset Composition Trend (2006–2024)
This chart illustrates how Eterna Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Eterna Therapeutics Inc (ERNA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eterna Therapeutics Inc's current assets represent 44.6% of total assets in 2024, a decrease from 60.5% in 2006.
- Cash Position: Cash and equivalents constituted 32.8% of total assets in 2024, up from 0.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 38.8% of total assets.
Eterna Therapeutics Inc Competitors by Total Assets
Key competitors of Eterna Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Eterna Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.58 | 0.48 | 0.55 |
| Quick Ratio | 1.58 | 0.48 | 0.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.24 Million | $-5.22 Million | $-1.39 Million |
Eterna Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Eterna Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.63 |
| Latest Market Cap to Assets Ratio | 0.84 |
| Asset Growth Rate (YoY) | -89.3% |
| Total Assets | $5.27 Million |
| Market Capitalization | $4.44 Million USD |
Valuation Analysis
Near Book Valuation: The market values Eterna Therapeutics Inc's assets close to their book value (0.84x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Eterna Therapeutics Inc's assets decreased by 89.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Eterna Therapeutics Inc (2006–2024)
The table below shows the annual total assets of Eterna Therapeutics Inc from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.27 Million | -89.28% |
| 2023-12-31 | $49.13 Million | +120.53% |
| 2022-12-31 | $22.28 Million | -29.33% |
| 2021-12-31 | $31.52 Million | +144.27% |
| 2020-12-31 | $12.91 Million | -15.51% |
| 2019-12-31 | $15.28 Million | +2.77% |
| 2018-12-31 | $14.86 Million | -10.30% |
| 2017-12-31 | $16.57 Million | -3.30% |
| 2016-12-31 | $17.14 Million | +1.86% |
| 2015-12-31 | $16.82 Million | -24.45% |
| 2014-12-31 | $22.27 Million | +44.06% |
| 2013-12-31 | $15.46 Million | +22.13% |
| 2012-12-31 | $12.66 Million | +8.66% |
| 2011-12-31 | $11.65 Million | -11.26% |
| 2010-12-31 | $13.12 Million | -8.20% |
| 2009-12-31 | $14.30 Million | +22.59% |
| 2008-12-31 | $11.66 Million | -44.09% |
| 2007-12-31 | $20.86 Million | -21.36% |
| 2006-12-31 | $26.52 Million | -- |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the tr… Read more